Recombinant Mouse Integrin alpha V beta 8 Protein, CF

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse Integrin alpha V beta 8 Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. Immobilized Recombinant Mouse Integrin alpha V beta 8 at 2 μg/mL can bind Recombinant Human LAP (TGF-beta 1) (Catalog # 246-LP) with an apparent K_d <0.1 nM.
• Source: Chinese Hamster Ovary cell line, CHO-derived mouse Integrin alpha V beta 8 protein
  

  Mouse Integrin aV (Phe31-Val988) Accession # P43406	His-Pro	GGGSGGGS	Acidic Tail	6-His tag
  Mouse Integrin beta 8 (Glu43-Ser679) Accession # Q0VBD0	His-Pro	GGGSGGGS	Basic Tail
  N-terminus				C-terminus

• Accession #: P43406 & Q0VBD0
• N-terminal Sequence: Phe31 ( alpha V subunit) & Glu43 ( beta 8 subunit)
• Structure / Form: Non-covalent heterodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 115 kDa ( alpha V subunit), 78 kDa ( beta 8 subunit).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 95 - 170 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS and Trehalose.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse Integrin alpha V beta 8 Protein, CF

• Integrin alpha V beta 8

Background

Integrin  alpha V beta 8 is a type I transmembrane non-covalent heterodimer composed of a 115 kDa alpha V/CD51 subunit and an 84 kDa beta 8 subunit. The Integrin  beta 8 exclusively partners with the alpha V subunit, while alpha V forms heterodimers with beta 1, beta 3, beta 5 and beta 6 (1). Integrin  alpha V beta 8 is expressed on Schwann cells and astrocytes in the brain, vascular epithelial cells, mesangial cells in the kidney, and fibroblasts and epithelial cells in the airway (2-7). Interestingly, Integrin alpha V beta 8 is expressed by cells of the immune system, most prominently on CD4⁺ T cells and on dendritic cells (8). Unlike other alpha V integrins, alpha V beta 8 does not interact with the cytoskeleton or activate cytoplasmic signaling pathways (3, 9). Instead, it binds ligands containing an arginine-glycine-aspartic acid (RGD) motif, including Vitronectin, Fibrin and the latency associated peptide (LAP) (10, 11). High affinity binding of alpha V beta 8 to LAP triggers the MT1-MMP induced proteolytic cleavage of LAP and the release of active TGF-beta (12). Active TGF-beta regulates cell growth and nearby vascularization (5, 12, 13). Furthermore, Integrin alpha V beta 8-mediated TGF-beta activation in specialized dendritic cells of the intestine is crucial for maintaining immune homeostasis in the gut (14). Deletion of either alpha V or beta 8 reveals that alpha V beta 8 is required for vascular morphogenesis in the embryonic brain (15-16). The 958 amino acid mouse alpha V extracellular domain (ECD) shares 92% and 88% aa sequence identity with human and rat alpha V, respectively, while the 637 aa mouse beta 8 ECD shares 87% and 96% aa sequence identity with human and rat orthologs, respectively.

1. Luo, BH. et al. (2007) Annu.Rev.Imm.25:619.
2. Milner, R. et al. (1997) Glia 21:350.
3. Nishimura, S. et al. (1998) Brain Res. 791:271.
4. Zhu, J. et al. (2002) Development 129:2891.
5. Cambier, S. et al. (2000) Cancer Res. 60:7084.
6. Khan, S. et al. (2011) Am. J. Pathol. 178:609.
7. Araya, J. et al. (2006) Am. J. Pathol. 169:405.
8. Travis, M.A. et al. (2007) Nature 449:361.
9. Moyle, M. et al. (1991) J. Biol. Chem. 266:19650.
10. Nishimura, S. et al. (1994) J. Biol. Chem. 269:28708.
11. Chernousov, M. A. and D. J. Carey (2003) Exp. Cell Res. 291:514.
12. Mu, D. et al. (2002) J. Cell Biol. 157:493.
13. Araya, J. et al. (2006) Am. J. Pathol. 169:405.
14. Worthington, J.J. et al. (2012) Immunobiology 217:1259.
15. Cambier, S. et al. (2005) Am. J. Pathol. 166:1883.
16. Proctor, J. M. et al. (2005) J. Neurosci. 25:9940.
17. McCarty, J. H. et al. (2005) Development 132:165.

Publications for Integrin alpha V beta 8 (8314-AV)(1)

Publication using 8314-AV

• M Bieri, R Hendrickx, M Bauer, B Yu, T Jetzer, B Dreier, PRE Mittl, J Sobek, A Plückthun, UF Greber, S Hemmi The RGD-binding integrins alphavbeta6 and alphavbeta8 are receptors for mouse adenovirus-1 and -3 infection PloS Pathogens, 2021-12-15;17(12):e1010083. 2021-12-15 [PMID: 34910784] (Bioassay, Mouse)

Bioinformatics

• Uniprot:
  • P43406 & Q0VBD0()